Apyx Medical (APYX) Scheduled to Post Quarterly Earnings on Thursday

Apyx Medical (NASDAQ:APYX – Get Rating) is scheduled to issue its quarterly earnings data before the market opens on Thursday, March 16th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Apyx Medical Trading Down 3.5 %

Shares of APYX opened at $2.79 on Tuesday. The company has a market capitalization of $96.53 million, a PE ratio of -4.98 and a beta of 1.29. Apyx Medical has a 12 month low of $1.31 and a 12 month high of $11.15. The stock’s 50-day moving average price is $2.96 and its two-hundred day moving average price is $3.46.

Wall Street Analysts Forecast Growth

APYX has been the topic of several recent research reports. Craig Hallum cut their target price on Apyx Medical to $10.00 in a report on Wednesday, November 16th. Piper Sandler cut their target price on Apyx Medical to $3.00 in a report on Wednesday, November 16th. Finally, Lake Street Capital reaffirmed a “buy” rating and set a $5.00 target price on shares of Apyx Medical in a report on Thursday, December 8th.

Hedge Funds Weigh In On Apyx Medical

A number of hedge funds and other institutional investors have recently modified their holdings of APYX. Tower Research Capital LLC TRC lifted its stake in Apyx Medical by 3,565.1% in the third quarter. Tower Research Capital LLC TRC now owns 7,147 shares of the company’s stock valued at $32,000 after purchasing an additional 6,952 shares during the last quarter. Advisor Group Holdings Inc. increased its stake in Apyx Medical by 94.1% in the fourth quarter. Advisor Group Holdings Inc. now owns 19,594 shares of the company’s stock valued at $46,000 after acquiring an additional 9,498 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in Apyx Medical in the second quarter valued at $73,000. MetLife Investment Management LLC increased its stake in Apyx Medical by 57.0% in the first quarter. MetLife Investment Management LLC now owns 18,314 shares of the company’s stock valued at $120,000 after acquiring an additional 6,649 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Apyx Medical by 33.5% in the second quarter. Goldman Sachs Group Inc. now owns 22,241 shares of the company’s stock valued at $130,000 after acquiring an additional 5,580 shares during the last quarter. Hedge funds and other institutional investors own 65.55% of the company’s stock.

Apyx Medical Company Profile

(Get Rating)

Apyx Medical Corp. operates as an energy-based medical technology company. The firm engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Advanced Energy and Original Equipment Manufacture (OME).